<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03502356</url>
  </required_header>
  <id_info>
    <org_study_id>2377</org_study_id>
    <nct_id>NCT03502356</nct_id>
  </id_info>
  <brief_title>Addition of Azithromycin to Cefazolin Will Reduce Post CS Infections More Than Cefazolin Only.</brief_title>
  <official_title>ADDATION OF Azithromycin TO CEFAZOLIN PRE ELECTIVE C S</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The good standard antibiotic prophylaxis pre elective C S is cefazolin and this study will
      approve addition of azithromycin to cefazolin will reduce post CS infections more than
      cefazolin only.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patiants and methods

      Randomization:

      Patients fulfilling the inclusion criteria will be randomized to two groups. Both two group
      will receive standard prophylaxis antibiotic CEFAZOLIN (zinol) (at a dose of 1 g) 2 hours
      preoperative.

      Control Group:

      This group will include 200women undergoing elective cs. In this group, patients will receive
      standard antibiotic prophylaxis CEFAZOLIN (at a dose of 1 g) and azithromycin (at a dose of
      1g) 2 hours preoperative.

      Study Group:

      This group will include 200women undergoing elective cs. In this group, patients will receive
      only standard prophylaxis antibiotic(CEFAZOLIN)

      Inclusion criteria:

        -  Gestational age of 37 0/7 weeks and greater

        -  Elective cesarean section

        -  Medicaly free pregnant women

      Exclusion criteria:

        -  a known allergy to azithromycin

        -  obstetric complications

        -  azithromycin use within 7 days before randomization

        -  chorioamnionitis or other infection requiring postpartum antibiotic therapy

        -  Pre-gestational diabetes
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 20, 2018</start_date>
  <completion_date type="Anticipated">August 20, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 20, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Control Group:
This group will include 200women undergoing elective cs. In this group, patients will receive standard antibiotic prophylaxis CEFAZOLIN (at a dose of 1 g) and azithromycin (at a dose of 1g) 2 hours preoperative.
Study Group:
This group will include 200women undergoing elective cs. In this group, patients will receive only standard prophylaxis antibiotic(CEFAZOLIN)</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>endometritis</measure>
    <time_frame>6 weeks after surgery</time_frame>
    <description>Endometritis was defined as the presence of at least two of the following signs with no other recognized cause: fever (temperature of at least 38°C [100.4°F]), abdominal pain, uterine tenderness, or purulent drainage from the uterus</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Randomized Controll Trial</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will include 200women undergoing elective cs. In this group, patients will receive standard antibiotic prophylaxis CEFAZOLIN (at a dose of 1 g) and azithromycin (at a dose of 1g) 2 hours preoperative.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group will include 200women undergoing elective cs. In this group, patients will receive only standard prophylaxis antibiotic(CEFAZOLIN)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>In this group, patients will receive standard antibiotic prophylaxis CEFAZOLIN (at a dose of 1 g) and azithromycin (at a dose of 1g) 2 hours preoperative.</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>Cefazolin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gestational age of 37 0/7 weeks and greater

          -  Elective cesarean section

          -  Medicaly free pregnant women

        Exclusion Criteria:

          -  a known allergy to azithromycin

          -  obstetric complications

          -  azithromycin use within 7 days before randomization

          -  chorioamnionitis or other infection requiring postpartum antibiotic therapy

          -  Pre-gestational diabetes
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>mohamed 20 amar, md</last_name>
    <role>Study Chair</role>
    <affiliation>ain shams</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>mohamed 20 amar, md</last_name>
    <phone>01024706467</phone>
    <phone_ext>02</phone_ext>
    <email>drmohamed145@gmil.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ain Shams</name>
      <address>
        <city>Cairo</city>
        <state>Elabasy</state>
        <zip>23</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>mohamed 20 amar, md</last_name>
      <phone>01024706467</phone>
      <phone_ext>02</phone_ext>
      <email>drmohamed145@gmil.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2018</study_first_submitted>
  <study_first_submitted_qc>April 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2018</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>mohamed abd elhamied abd elgaber</investigator_full_name>
    <investigator_title>cario egypt</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Cefazolin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

